Parkinson’s disease (PD) is an incurable, chronic neurological disorder of largely unknown etiology, characterized by degeneration of dopaminergic neurons and the subsequent loss of dopamine throughout the brain. The symptoms of PD typically begin following the loss of 60–80% of the dopamine-producing cells in the brain, with symptoms continuing to worsen slowly over time. Advanced PD (APD) represents a progressed form of PD, characterized by symptoms that are refractory to best medical therapy (BMT). Treatment options for patients with APD who develop resistance to BMT are limited and consist mainly of three device-aided interventions: deep brain stimulation (DBS), levodopa/carbidopa intestinal gel (LCIG), and continuous subcutaneous apomorphine infusion (CSAI). Our client wanted to conduct a systematic literature review of on on the efficacy, safety, tolerability, and quality of life (QoL) of LCIG, CSAI, and DBS in advanced PD patients. In order to assist our client, we screened approximately 2285 studies for 1st pass and 190 studies for 2nd pass screening phase. Twenty nine articles were finally extracted and the findings of which helped the client in report writing.